Literature DB >> 24792030

A single injection of intravitreal ranibizumab in the treatment of choroidal neovascularisation secondary to optic nerve head drusen in a child.

Zeynep Alkin1, Abdullah Ozkaya, Ihsan Yilmaz, Ahmet Taylan Yazici.   

Abstract

Optic nerve head drusen are acellular, calcified deposits which may be found in buried or exposed drusen form. Choroidal neovascularisation secondary to optic nerve head drusen is rarely seen in childhood. This case report summarises the clinical and therapeutic outcomes of a 13-year-old girl with unilateral choroidal neovascularisation secondary to optic nerve head drusen. The patient was successfully treated with a single intravitreal ranibizumab injection. After a month from the injection the visual acuity increased dramatically and maintained at the same level during 9 months of follow-up time. There was no complication related to the injection.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24792030      PMCID: PMC4025440          DOI: 10.1136/bcr-2014-204456

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  9 in total

1.  Surgical removal of peripapillary choroidal neovascularization associated with optic nerve drusen.

Authors:  Carlos Mateo; Javier G Moreno; Miguel Lechuga; Alfredo Adán; Borja Corcóstegui
Journal:  Retina       Date:  2004-10       Impact factor: 4.256

2.  Bilateral CNV associated with optic nerve drusen treated with photodynamic therapy with verteporfin.

Authors:  R Silva; T Torrent; R Loureiro; A Travassos; J Rui Faria de Abreu
Journal:  Eur J Ophthalmol       Date:  2004 Sep-Oct       Impact factor: 2.597

3.  Long term follow-up after a single intravitreal ranibizumab injection for choroidal neovascularisation secondary to optic nerve head drusen in a 5-year-old child.

Authors:  Stéphanie Baillif; Elisabeth Nguyen; Anne Colleville-El Hayek; Frédéric Bétis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-10-24       Impact factor: 3.117

4.  Successful Treatment of Subretinal Neovascularization with Intravitreal Ranibizumab in a Child with Optic Nerve Head Drusen.

Authors:  Kevin Gregory-Evans; Poornima Rai; Julian Patterson
Journal:  J Pediatr Ophthalmol Strabismus       Date:  2009-08-21       Impact factor: 1.402

5.  Intravitreal bevacizumab treatment of bilateral peripapillary choroidal neovascularization from optic nerve head drusen.

Authors:  Robert M Knape; Eric M Zavaleta; Charles L Clark; Nausheen Khuddus; Marc C Peden
Journal:  J AAPOS       Date:  2011-02       Impact factor: 1.220

6.  Ophthalmic features of optic disc drusen.

Authors:  Patricia Flores-Rodríguez; Pablo Gili; María Dolores Martín-Ríos
Journal:  Ophthalmologica       Date:  2012-05-12       Impact factor: 3.250

7.  Laser photocoagulation for choroidal neovascular membrane associated with optic disc drusen.

Authors:  Marie N Delyfer; Marie B Rougier; Eric Fourmaux; Philippe Cousin; Jean-François Korobelnik
Journal:  Acta Ophthalmol Scand       Date:  2004-04

Review 8.  Optic disk drusen.

Authors:  Claudia Auw-Haedrich; Flemming Staubach; Heinrich Witschel
Journal:  Surv Ophthalmol       Date:  2002 Nov-Dec       Impact factor: 6.048

9.  Bilateral choroidal neovascularization associated with optic nerve head drusen treated by antivascular endothelial growth factor therapy.

Authors:  Barbara Delas; Lorena Almudí; Anabel Carreras; Mouafk Asaad
Journal:  Clin Ophthalmol       Date:  2012-02-13
  9 in total
  3 in total

1.  Paediatric case of peripapillary choroidal neovascularisation associated with optic disc drusen treated with aflibercept.

Authors:  Weh Loong Gan; Vernon W Long
Journal:  BMJ Case Rep       Date:  2019-01-14

Review 2.  Optic disk drusen in children.

Authors:  Melinda Y Chang; Stacy L Pineles
Journal:  Surv Ophthalmol       Date:  2016-03-29       Impact factor: 6.048

3.  Optic Coherence Tomography Angiography Findings of Bilateral Choroidal Neovascularization Associated with Optic Disc Drusen Treated with Intravitreal Aflibercept Injection.

Authors:  Melih Akıdan; Mehmet Bulut; Lütfiye Yaprak; Muhammet Kazım Erol; Elcin Suren
Journal:  Case Rep Ophthalmol Med       Date:  2020-03-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.